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Summary 
Oligonucleotides encoding peptides known to bind to HLA-DR1 molecules have been inserted 
into the gene III of filamentous M13 phages. DR1 molecules purified from human lymphoblastoid 
cell lines could specifically bind to these peptide sequences expressed on the phage surface.  A 
M13 phage peptide library was next constructed and screened with DR1 molecules. After four 
rounds of selection, more than 80%  of the phages were able to bind to DR1.  Competition 
experiments with both isolated phages and corresponding synthetic peptides showed that the 
binding was specific. Sequence analysis  of the peptide encoding region of 60 phages binding 
to DR1 molecules and comparison with phages of the original library revealed two potential 
anchor positions. The first was an aromatic residue (Tyr, Phe, or Trp) at the NH2 terminus of 
the peptide sequences,  and the second was located three residues downstream and consisted of 
Met or Leu. In addition, the negatively charged amino acids Asp and Glu were mostly excluded 
from the DR1 binding sequences, and the small amino acid residues Gly and Ala were enriched 
at position 6.  As for DR1,  this approach should enable one to easily determine the binding 
motifs of other MHC class II alleles and isotypes. Furthermore, it could have interesting applications 
in the design of major histocompatibility complex-specific antagonists. 
T 
he MHC class II molecules are highly polymorphic mem- 
brane glycoproteins that bind peptide fragments of pro- 
teins and display these peptides for recognition by CD4 + T 
cells (1). Because one individual expresses only a limited set 
of different MHC molecules, every molecule must be able 
to bind a large number of diverse peptides to guarantee T 
cell-mediated immunity to the universe of antigens. Neverthe- 
less, any given class II molecule shows some selectivity in 
its ability to bind peptides. 
Different approaches have been taken to determine motifs 
of peptide-binding to MHC molecules. Using the Edman 
degradation method (2-4) and more recently, tandem mass 
spectroscopy (5), endogenous peptides of various MHC class 
I alleles were sequenced, and position-dependent enrichment 
of particular amino acids  have been demonstrated. 
For class II molecules some peptide residues involved in 
MHC interaction have been identified using peptide analogs 
with single amino acid substitution or biotinylated amino 
acids  (for  review  see  reference 6).  In  addition,  naturally 
processed peptides of foreign proteins bound to self class II 
molecules have been identified (7). However, the endogenous 
peptides analyzed consisted of only a few different peptides 
and no clear binding motifs could be defined. 
We have chosen a new approach to define the characteris- 
tics of peptides binding to MHC class II molecules. Here, 
we demonstrate that class II molecules were able to bind pep- 
tides displayed on a phage surface.  This allowed us to use 
M13 peptide libraries (8-10) to screen for phages that bind 
to HLA-DR1 molecules. The comparison of the peptide pool 
binding to DR1 with the original peptide pool of the M13 
library revealed  new insights in peptide-DR1  interaction. 
Materials  and Methods 
Reagents and Strains.  M13mp19, Escherichia coli XLIBlue and 
SCS1 were obtained from Stratagene Inc. (La JoUa, CA). Oligonu- 
cleotides were obtained from MedProbe (Oslo, Norway). Peptides 
were synthesized with a MiUiGen  peptide synthesizer (model 9050; 
MiUigen/Bioresearch,  Burlington, MA) using Fmoc chemistry, and 
were purified by preparative reverse-phase (RP)  HPLC.  Homo- 
geneity of each peptide was confirmed by analytical RP-HPLC. 
Characterization was performed by fast atomic bombardment-mass 
spectroscopy  (FAB-MS), and expected  molecular  ions were observed. 
Streptavidin on 4% beaded agarose and bovine albumin, fraction 
V, were obtained from Sigma Chemical Co. (St. Louis, MO). Biotin- 
XX-NHS was from Calbiochem Corp. (LaJoUa, CA). MAb L243 
(IgG2a) recognizing the DR heterodimer (11) was used as purified 
immunoglobulins. The hybridomas cells were obtained from the 
American Type Culture Collection (Rockville, MD). 
Purification  and Biotinylation of  HLA-DR1.  DR1 molecules  were 
isolated from the human EBV-B cell line, HOM-2, as described 
elsewhere (12). A 10-#M solution of atfinity-purified  DR1 was bio- 
tinylated with 200 #M Biotin-XX-NHS  in 0.25 M NaHCO3/ 
0.2%  NP-40 for 1 h at room temperature. 
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follows. A B-lactamase gene was obtained by PCIL amplification 
using the plasmid pUC 19 and the two oligonucleotides 5-ACG 
TGG ATC CGT ATA TAT GAG TAA ACT TGG-3 and GTA AGG 
GAA TTC GGG AAA TGT GCG CGG AAC CC-3. The PCR 
product was digested with EcoRI and BamHI and placed into the 
corresponding sites of the M13mp19 polylinker. To construct the 
library vector M13stufferbb, the sequence CTC CGC TGA of the 
protein III coding region of M13amp was converted to CTC GGC 
CGA by in vitro mutagenesis to create an EclXI site. The two oli- 
gonucleotides 5-GGC CGA GCT CGG TCA AGC TGA CGA 
AGC TGC GGT ACC-3 and 5-GGC CGG TAC CGC AGC TTC 
GTC AGC TTG ACC GAG CTC-3 were annealed and inserted 
into the EclXI site to create a stuffer with a SacI and KpnI site. 
For the construction of  M13HA, M13TT and M13NNX, the vector 
M13stufferbb was digested with Sad and KpnI and the stuffer was 
removed. The following oligonucleotides were annealed and in- 
serted to replace the stuffer: 5-CGG TGG TGG TCC GAA ATA 
CGT TAA ACA GAA CAC CCT GAA ACT GGC TAC CGG 
CGG CGG CGG GGT AC-3 and 5-CCC GCC GCC GCC GGT 
AGC CAG TTT CAG GGT GTT CTG TTT AAC GTA TTT 
CGG ACC ACC ACC GAG CT-3 for MDHA; 5-CGG TGG TGG 
TTC CGG TCC GGA CAA AGA ACA GAT CGC TGA CGA 
AAT CAA CGG CGG CGG CGG GGT AC-3 and 5-CCC GCC 
GCC GCC GTT GAT TTC GTC AGC GAT CTG TTC TTT 
GTC CGG ACC GGA ACC ACC ACC GAG CT-3 for M13T'I~ 
and 5-CGG TGG CGG CAA CGC TCT GTA CAA ATT GAA 
CGC TGT TGC TGC GGC CGC AGG GGG AGG AGG GGT 
AC-3 and 5-CCC TCC TCC CCC TGC GGC CGC AGC AAC 
AGC GTT CAT TTT GTA CAG AGC GTT GCC GCC ACC 
GAG CT-3 for M13NNX. 
Construction of the M13 Peptide Library.  The library  was  in 
principle constructed  as  described (8-10),  with  some changes. 
MDstufferbb DNA was digested to completion with Sad and KpnI, 
and the stuffer was removed by gel electrophoresis to reduce any 
background. A random oligonucleotide  5-C GGT GGC GC~ GGT 
(NNS)9 GGG GGA  GGA  GGG GTA C-3  (S=G,C  and  N= 
G,C,T,A) encoding two flanking polyglycine spacers and a random 
core nonamer was annealed  to two half-site  oligonudeotides 5-ACC 
GCC GCC ACC GAG CT-3 and 5-CCC TCC TCC CCC-3 in 
a 1:1:1 ratio. The digested M13stufferbb DNA was ligated to the 
annealed oligonucleotides  in a estimated 1:5 ratio. The ligated DNA 
was transformed by dectroporation into E. coli SCS1 cells. Twenty 
transformations,  each containing  40/~1 of ceils and ,~200 ng of 
ligated DNA, were performed to produce 24 million independent 
clones. The library was amplified in LB3/ampicillin media as de- 
scribed (10). The overall amplification factor was 104  . 
M13DR1 Binding Assay.  Up to 1 billion M13 phages displaying 
peptides of  known or random sequences  were mixed with a similar 
number of MDmp19 phages as a reference  and incubated with 10-50 
pmol biotinylated DR1 in binding buffer (50 mM Tris-C1, pH 7.5, 
150 mM NaC1, 1 mM EDTA, 1 mM PMSF, and 0.2% NP-40). 
After at least 24 h incubation at room temperature, BSA-blocked 
streptavidin on 4% beaded agarose was added and incubated for 
10 min. The M13 phage/DR1 complexes  were purified by washing 
the solid phase several times with binding buffer. In some experi- 
ments, an additional wash step with 70 mM citrate-phosphate pH 
3/500 mM NaC1 was performed. The phages were eluted with 
dution buffer (0.1 N glycine-HC1, pH 2.2, 1 mg/ml BSA) for 10 
rain and neutralized with 2 M Tris base as described (8-10). Up 
to 40 binding reactions have been performed simultaneously. The 
ratio of the phages displaying peptides to M13mp19 phages was 
determined in the initial mixture and the eluates by plating both 
on X-Gal indicator plates. An enrichment  of white (phages dis- 
playing peptides) vs. blue plaques (M13mp19) indicated peptide- 
based binding  (9). 
Library Screening.  20 billion phages of the amplified M13 pep- 
tide library were incubated with DILl under the same conditions 
as described for the M13/DR1 binding assay. The phage eluate 
was concentrated and washed with 150 mM NaCI/50 mM Tris- 
C1, pH 7.5 by ultradialization (Microsep Microconcentrator 30 k 
cutoff, Filtron Technology Corp., Northborough, MA). Up to 10 
million eluted phages were used to infect 500 #1 ofE. coli  XLlblue 
plating cells (OD=I). The infected cells were transferred to 7 ml 
Luria-Bertoni (LB)  1 media in a 25-cm  2 tissue culture flask. After 
1 h incubation  (37~  rpm), ampicillin was added to a final 
concentration  of 20  /lg/ml.  After  overnight  incubation,  the 
amplified phages were harvested and purified twice with polyeth- 
ylene glycol. The screening procedure was repeated three times. 
The eluate of the fourth round was used to isolate and sequence 
individual MD clones. 
Peptide/DR1 Binding Assay.  The binding assay was performed 
as previously described (12a). Briefly, 25 pmol of affinity-purified 
DILl  and  30  pmol  of  nSI-radiolabeled hemagglutinin  (HA) 
307-319 peptide were mixed in binding buffer. After incubation 
for 24 h at 37~  the samples were applied onto columns (Bio- 
Spin 30; Bio-Rad Laboratories, Richmond, CA) and centrifuged 
at 1,100 g for 2 rain.  The radioactivity in the void volume was 
directly counted in a y-scintillation  counter. To measure specific 
binding of other peptides to DR1, indicated amounts of unlabeled 
peptides were added to the reaction mixture,  and their ability to 
compete with the labeled HA peptide was determined as described 
above. 
Results 
Specific Interaction of Dgl Molecules with Peptides Displayed 
on the Phage Su~ce.  To investigate whether HLA-DR mol- 
ecules were able to bind peptides displayed on phage surfaces, 
peptides known to bind to DR1 were placed on the NH2 
terminus of the MD phage protein III (Table 1). The protein 
III is a minor coat protein of the M13 phage and the region, 
containing the peptide inserts, is known to be exposed on 
the phage surface (13). The peptide sequences were flanked 
by two glycine spacers to maximize the flexibility of the pep- 
tide insert. 
Fig.  1 a  shows that the M13 constructs bind specifically 
to DR1 molecules. M13 phages (MDHA and M13NNX), 
displaying the DR1 binding influenza HA 307-319  peptide 
(14) and the Plasmodium falciparum NNX 83-91  (Sinigaglia, 
F., unpublished observation), bound to DR1 molecules, as 
judged by the enrichment of M13HA and M13NNX phages 
versus the M13mp19 reference phages (90-95% specific phage 
binding).  Conversely, phages displaying the tetanus toxoid 
(TT) sequence 763-775, used here as a negative control, did 
not bind to DR1. The ability of the DRl-binding synthetic 
peptides HA 307-319 and TT 830-843 (15) to compete with 
the phage-DR1 binding (Fig.  1 b) provided additional evi- 
dence that the binding occurred in the peptide-binding groove. 
Construction of a M13 Peptide Library and Isolation of Phages 
I Abbreviations  used in this paper: HA, hemagglutinin; LB, Luria-Bertoni 
medium; RP, reverse  phase; TT, tetanus toxoid. 
1008  DRl-specifir Motif Table  1.  Phage Constructs 
Phage  NH2 terminal region of M13  phage pII1  Peptide 
M13HA  AEL GGG PKYVKQNTLKLAT GGGG VP -  pill  HA 307-319 
M13NNX  AEL GGG NALYKMNAVAKAA GGGG VP -plII  NNX  83-91 
M13TT  AEL GGG SGPDKEQIADEIN GGGG VP - plII  TT 763-775 
M131ib  AEL GGGG XXXXXXXXX  GGGG VP  -plII  Random oligo 
The NH2 terminal region of the modified M13 protein III of each construct is shown. Amino acid sequences of peptides with known binding charac- 
teristics to DR1 (HA, NNX, and TT) and the random peptide region of the M13 peptide library are underlined. The single letter code for amino 
acids is: A  =  Ala, D  =  Asp,  E  =  Glu, F  =  Phe,  G  =  Gly, H  =  His, I  =  Ile, K  =  Lys, L  =  Leu, M  =  Met, N  =  Asn, P  =  Pro, Q  = 
Gin, R  =  Arg, S  =  Ser, T  =  Thr, V  =  Val,  W  =  Trp, Y  =  Tyr, and X  =  random amino acid. 
Binding to DRI.  The oligonucleotides encoding peptides of 
known binding characteristics were replaced by random oli- 
gonucleotides, and a M13 peptide library with 20 million 
independent phages was generated (M13Lib). The random 
peptide inserts were nine amino acid residues in length and 
flanked by four glycines on each side (Table 1). Four rounds 
of successive selection and amplification were performed. To 
monitor the enrichment for DR1 binders,  the binding ca- 
pacity of the libraries was tested before and after each round 
of screening (Fig. 2 a). Whereas the original library (M131ib) 
did not show any binding to DR1, the DR-1 selected  libraries, 
after three and four rounds of screening, showed binding that 
was of a similar magnitude to that obtained with M13HA 
phages (20 times M13mp19 background). The binding was 
specific as judged by peptide competition assays (not shown). 
Individual phages  were then isolated  and tested  for DR1 
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Figure 1.  DR.1 molecules bind 
specifica[ly  to peptides displayed on 
the phage  surface. (a) M13/DR1 
binding  assay. Binding  of M13 con- 
structs to DR1 was determined by 
their enrichment as compared with 
the reference phage M13mp19. For 
M13 constructs,  the phage  input 
was I billion, and for M13mp19, 2 
billion. (b) Phage/Ix-pride competi- 
tion assay. Increasing amounts of 
peptides were added to compete for 
DR1/M13HA phage binding. Bind- 
ing and dution conditions were the 
same  as  in a.  Peptide  from  the 
human  acetylcholine  receptor 
subunit  (AchR 4-15) was  used 
as negative control Phage input: 
M13HA, 2 billion. 
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Figure  2.  M13/DR1  binding 
assay with whole libraries and iso- 
lated phages. (a) DR.1 binding to 
the original library (M131ib)  and to 
the  amplified  libraries  after  each 
round of screening was determined 
by the enrichment of the library 
phages as compared with the refer- 
ence phages (M13mp19). (b) Nine 
phages before and after four rounds 
of  screening  were  isolated,  and 
binding  to DR1 was determined for 
each phage as in a. 
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Figure 3.  Inhibition curves for peptides based on sequences corresponding 
to those of three randomly selected DRl-bound phages (M13P1-6,  M13PI-11, 
and MI3PI.12). t2SI-labeled HA 307-319 and HLA-DR.1 were incubated 
in the presence  of indicated concentrations of the following peptides: 
M13P1-6 (GGYRHAQAYGVGG), M13P1-11 (GGWFGQLQAAQGG), 
and M13Pl-12 (GGYRQMSAPTLC~). HA 307-319 and AchR 4-15 were 
used as positive and negative controls, respectively. The samples were ana- 
lyzed by spin column gel filtration as described in Materials and Methods. 
The sequences of the peprides M13P1-6, M13Pl-11,  and M13P1-12 cor- 
respond to the peptide encoding regions of DR1 selected phages and are 
flanked by two Gly on both sites to standardize the length with that of 
the control peptides. 
binding. As shown in Fig. 2 b, eight of nine phages isolated 
after four rounds of screening bound to DR1, whereas none 
of the phages isolated from the original library did. As above, 
the specificity of the phage-DR interaction was demonstrated 
by phage-peptide competition assays (data not shown). We 
next sequenced the peptide-encoding region of three of these 
phages and corresponding peptides were synthesized. The 
three peptides were indeed able to bind to DR1 with binding 
capacities within the same range of the HA 307-319 peptide 
(ri . 3). 
oequence Motifs of DRl-binding Peptide Inserts.  To inves- 
tigate the structural characteristics  of peptides capable  of 
binding to DR1 molecules, the peptide-encoding regions of 
60 DRl-binding phages were sequenced (Table 2). All pep- 
tides sequenced were different, which confirms the indepen- 
dent origin of the phages analyzed. When the overall amino 
acid composition of the sequences listed in Fig. 5 was com- 
pared with sequences of 60 control phages isolated from the 
original library,  and of 35 control phages that also under- 
went three rounds of amplification (but without DR1 selec- 
tion), several differences were noted (Fig.  4 a).  The most 
striking difference was a significant enrichment of Met and 
Tyr, whereas the negatively charged amino acids Asp and Glu 
were almost absent from the DR1 binding sequences. As 
shown in Fig. 4, b and c, enrichment of a specific amino acid 
depends on the position within the peptide sequence.  Al- 
though Tyr is mainly located at the NH2 terminus of the 
peptide insert, the peak of Met is found in the middle. To 
determine the relative  positions of these potential anchor 
residues and to further identify structural characteristics  of 
the DRl-binding peptides, an unbiased alignment was per- 
formed using the "Pileup" program of the GCG (Genetics 
Computer Group Inc., Madison, WI) program package. The 
relative abundance of each amino acid at different positions 
of the aligned sequences is shown in Fig. 5.48% of the aligned 
sequences contain a Tyr residue at position 1. The other residues 
whose frequencies were dearly increased at this position were 
Phe (25%) and Trp (13%),  which also have aromatic side 
chains. In addition to the aromatic residues enriched at posi- 
tion 1, at position 4 we detected mostly Met (50%) and Leu 
(28%). Further constraints were found at position 6, which 
shows a preference for the small amino acids Ala (32%) and 
Gly (22%). The increased frequency of Gly at position 9 is 
due to the Gly of the spacer which shows up after the align- 
ment. If we only consider the amino acid residues  of the 
random peptide coding region, 45% of the peptides would 
have a Leu at position 9. 
Discussion 
MHC  class II molecules must bind a large number of 
different peptides to guarantee T cell-mediated immunity to 
Table  2.  Amino Acid Sequences of the Random Peptide Region of 60 Phages Bound to DRI 
MFQRMAVDA  YRQMSAPTL  WFGQLQAAQ  YRHAQAYGV  MPRQYTQMI  FHKVYRGLL 
WQMAMSRHL  SIMMMGAVR  WYTLLKSRL  YKPMLASVG  YAAMRGGQI  YKPLWGQMT 
NYQMMGTMR  FERARSRLL  YLRMLQILK  NWRALRGAL  YRQMWVNRA  FMAMRAVRL 
FTMLMNQVM  VYRAQGPQM  MMSRMLGQT  SSGRYARLG  TFYRMGTQM  WIGQMYAAK 
YRMQSNHVS  DRSMEWRMM  FSAIRNRIL  YRAMQTTLS  NYLGMKPRV  RGFRHMMAA 
YQQMGARLM  SWRHIQTRV  MYGLMLAQR  YQALRAYWQ  RFTQMMAVA  WKGLQGALS 
FMRLGGGHL  IWHMQNARV  YKLLRATQM  LWQSFMQMA  FHQLRGGSL  YRGMQRRTL 
YGKLRGGTL  QVGKYLGLG  TYRGMAGFR  RVFQNLRAS  WRQMYRAQL  RSYSLAPGR 
TWNSLRGRL  QRYNAMRAA  YIMQMNRVV  LTLMQAKRL  RFTQMGALA  YYGKMPALV 
PWQAMRGWL  KKIMSYHAL  YRGMSAFRA  MFHRMSGLQ  GQRSYSSMQ  YMMQKSVRA 
The phages were selected from the library M131ib by DR1  and isolated after four rounds of screening. 
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Figure  4.  (a) Amino acid content of the peptide inserts before and after 
DRI sdection.  The overall  amino  acid  composition  of  the sequences  listed 
in Table 2 was compared  with sequences  of 60 control phages, isolated 
from the original library, and of 35 control phages, that also underwent 
up to three rounds of amplification  but without DR1 selection.  Only the 
amino acids significantly  (>2%) increased  or reduced  are shown. (b and 
c) Position-specific  enrichment  of Tyr and Met after DR1 selection. 
the universe of foreign antigens. The binding of a peptide 
to a particular class II allele is nevertheless specific. From this, 
we can deduce that the amino acid residues of a peptide pool 
binding to a given class II molecule cannot be randomly dis- 
tributed over the peptide sequences, but rather have a defined 
distribution, reflecting the physicochemical properties needed 
for the interaction with that particular MHC molecule. The 
determination of these characteristics requires a large pool 
of peptides. Here we have chosen a new stochastic method 
to meet this requirement. 
As shown in Fig. 1, HLA-DR molecules were able to bind 
specifically to peptides displayed on the phage surface as part 
of the M13 phage protein III. This binding might be facili- 
tated by the exposure of the peptide insert on the phage sur- 
face and by its flexible conformation because of the presence 
of the Gly spacers. Our results also support previous obser- 
vations that some T cell clones appear to recognize complete 
folded protein antigens or denatured antigens without fur- 
ther processing (16,  17). From the proposed model of class 
II molecules (18), it is believed that both ends of the peptide- 
binding groove of MHC class II may be open, in contrast 
to MHC class I molecules where both ends are closed (19). 
This may explain why class II molecules, in contrast to dass 
I,  can even bind determinants on intact proteins. 
To construct our library, we chose a 9 met as a random 
peptide insert, as suggested by previous findings showing that 
the optimal peptide length for binding is between 8 and 12 
amino acids with the central 5-8 residues contributing the 
majority of the specific contacts (6,  20). 
By sequencing the inserts of 60 phages that bound HLA- 
DR1 molecules, we could identify a DR1 peptide-binding 
motif. At the NH2 terminus of the peptide-encoding region 
we found a striking predominance of aromatic residues. This 
is consistent with findings of Jardetzky et al. (21) showing 
the importance of Tyr~ for the interaction of HA 307-319 
with DR1. Three residues downstream, we identified a second 
restricted position with Met or Leu found in nearly 80% 
of the peptide sequences analyzed. Furthermore, the small 
amino acid residues Ala and Gly were significantly enriched 
at position 6. From these data we can deduce that DR1 mol- 
ecules possess a pocket for the aromatic side chains Tyr, Phe, 
or Trp, and perhaps another one able to accommodate Met 
or Leu (both hydrophobic with similar size). Although the 
side chains of the anchor amino acid positions might interact 
with specific pockets in the binding cleft of DR1,  the en- 
richment for small amino acids could instead reflect the fact 
that larger side chains at this position are not tolerated. In- 
deed in the class II model (18), a putative aromatic binding 
pocket has been identified in the ol1 domain of DR1 (Shira- 
tory, Y., and D.M. Doran, unpublished observation). This 
aromatic pocket is big enough to accommodate the entire 
tyrosine side chain. More detailed information on the three- 
dimensional structure of MHC class II molecules is required, 
however, to clarify the nature of the DR.1/peptide binding. 
Our results also show that certain amino acid residues are 
significantly reduced in DR1 binders. In particular, we found 
that the negatively charged amino acids Glu and Asp were 
virtually excluded from the DR1 binding sequences.  This 
indicates that in addition to specific anchor residues, the overall 
amino acid composition of a given peptide is important for 
MHC binding. 
Recently,  O'Sullivan  et  al.  (22)  have proposed  a  DR1 
binding motif by determining the effect of single amino acid 
substitutions of peptides HA 307-319  and TT 830-843  for 
binding to different DR alleles. The proposed motif consisted 
1011  Hammer et al. 50  position  1  position 2  position 3   Oll 
30  30  30 
il  ,o  i  ,I  h 
1o  1o  1o 
o  .  ~  ￿9  a .....  0  .  iI.hh  il  .  o  a  il  ..  I 
ADEFGH[KLMNPQRSTVWY  ADEFGHI  KLMNPQRSTVWY  AD EFGH~K  LMNPQRSTVWY 
50 
30 
20 
10 
0  ￿9 
ADEFGHI 
)osition 4 
.... I-- 
LMNPQRSTVWY 
position  5  50 
30 
0...ii.i  ili  el..  ￿9 
ADEFGHI  KL MNPQR STVWY 
position 6  50 
'~ 
3O 
20 
10 
o  .  J,  ill,. 
AD EFGH'I  KL MNP QRSTVWY 
Figure  5.  Position-specific  composition  of 
aligned DRl-bound peptide  sequences. The 60 
DRl-bound peptide sequences shown in Table 2 
were aligned using the PileUp program of  the GCG 
program package. Dark and light columns repre- 
sent the amino acids of the random peptide region 
or the Gly of the spacer, respectively. 
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of an aromatic or hydrophobic residue at the NH2 terminus 
of the peptide (position 1), a noncharged and relatively small 
residue at position 6,  and a relatively hydrophobic residue 
at position 9. Similar findings were also reported by Roth- 
bard et al. (23) using biotinylated analogs of the HA 307-319 
peptide. Our data are in substantial agreement with these 
results, except for the Met/Leu "anchor" described above. 
This difference is most likely due to the large number of pep- 
tides that have to be synthesized before one is really able to 
identify all the important positions for MHC-binding. In this 
respect, the possibility to analyze an almost unlimited number 
of peptide sequences using the M13 peptide library is cer- 
tainly a more powerful way to characterize MHC class II- 
binding motifs. 
The fact that not all the random peptide sequences con- 
tain all the anchor positions described, as the HA peptide 
does not have the internal Met or Leu at the predicted posi- 
tion, suggests that two or maybe only one critical residue 
may be sufficient for DR1 interaction. We are currently evalu- 
ating the relative influence of the different anchor residues 
for peptide binding. 
Using the approach described here, we are also defining 
motifs for other HLA class II alleles and isotypes with the 
aim of studying the effect, in terms of peptide binding, of 
discrete mutations in MHC class II molecules that are associ- 
ated with susceptibility to particular autoimmune diseases 
(for review see reference 24). Furthermore, the knowledge 
of anchor positions and other general rules of peptide-binding 
to MHC molecules should prove useful for the design of 
MHC-specific antagonists. 
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